We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $4.94B
1-Year Est. Return 244.43%
This Fund
S&P 500
This Quarter Est. Return
+34.74%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.33B
Cap. Flow
+$314M
Cap. Flow %
6.35%
Top 10 Hldgs %
44.63%
Holding
126
New
26
Increased
32
Reduced
21
Closed
9

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$82.7M
2
ABVX
Abivax
ABVX
+$65.2M
3
COAG
Hemab Therapeutics
COAG
+$57.6M
4
RLAY icon
Relay Therapeutics
RLAY
+$53M
5
KLRA
Kailera Therapeutics
KLRA
+$48.7M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$60.4M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$42.9M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$41.8M
4
RVMD icon
Revolution Medicines
RVMD
+$30.8M
5
KYMR icon
Kymera Therapeutics
KYMR
+$21.6M

Sector Composition

Rank Sector Weight
1 Healthcare 92.94%
2 Technology 3.57%
3 Communication Services 1.85%
4 Financials 0.87%
5 Consumer Discretionary 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRON icon
26
Disc Medicine
IRON
$2.65B
$65M 1.32%
888,401
-100,000
-10% -$6.87M
CYTK icon
27
Cytokinetics
CYTK
$9.6B
$64.7M 1.31%
758,952
+145,000
+24% +$10.4M
SEPN
28
Septerna Inc
SEPN
$1.84B
$63.6M 1.29%
1,900,000
-100,000
-5% -$2.84M
OLMA icon
29
Olema Pharmaceuticals
OLMA
$862M
$60.8M 1.23%
4,856,949
+100,000
+2% +$1.34M
CRNX
30
DELISTED
Crinetics Pharmaceuticals
CRNX
$53.2M 1.08%
1,420,788
-482,848
-25% -$17.9M
KLRA
31
Kailera Therapeutics
KLRA
$1.64B
$48.8M 0.99%
+2,214,286
New +$48.7M
DYN icon
32
Dyne Therapeutics
DYN
$3.32B
$47.3M 0.96%
2,129,125
-100,000
-4% -$1.86M
GPCR icon
33
Structure Therapeutics
GPCR
$2.52B
$46.9M 0.95%
872,967
-455,731
-34% -$20.2M
TBLA icon
34
Taboola.com
TBLA
$1.02B
$42.1M 0.85%
8,423,410
-1,546,085
-16% -$6.76M
PVLA
35
Palvella Therapeutics
PVLA
$2.21B
$39.3M 0.8%
257,485
– –
SLN
36
Silence Therapeutics
SLN
$786M
$36.4M 0.74%
3,311,438
+400,000
+14% +$2.81M
DNLI icon
37
Denali Therapeutics
DNLI
$3.23B
$35.9M 0.73%
1,396,513
– –
RELY icon
38
Remitly
RELY
$4.64B
$34.6M 0.7%
1,543,271
– –
CGEM icon
39
Cullinan Oncology
CGEM
$1.37B
$34.5M 0.7%
1,893,410
+700,000
+59% +$10.4M
COF icon
40
Capital One
COF
$125B
$34.4M 0.7%
+171,615
New +$32.8M
TRVI icon
41
Trevi Therapeutics
TRVI
$2.16B
$33.3M 0.67%
1,786,867
– –
ORIC icon
42
Oric Pharmaceuticals
ORIC
$1.32B
$32.5M 0.66%
2,998,192
– –
GOOGL icon
43
Alphabet (Google) Class A
GOOGL
$4.22T
$32.2M 0.65%
90,000
+24,297
+37% +$8.75M
DBVT
44
DBV Technologies
DBVT
$780M
$30.5M 0.62%
1,857,362
– –
ABSI icon
45
Absci
ABSI
$1.58B
$28.7M 0.58%
2,474,764
+674,764
+37% +$3.8M
SION
46
Sionna Therapeutics
SION
$348M
$26.9M 0.54%
610,515
+310,515
+104% +$12.4M
RAPP
47
Rapport Therapeutics
RAPP
$2B
$26.7M 0.54%
641,469
– –
AMLX icon
48
Amylyx Pharmaceuticals
AMLX
$3.76B
$26.6M 0.54%
1,480,586
+250,586
+20% +$3.88M
ANNX icon
49
Annexon
ANNX
$785M
$25.5M 0.52%
4,458,646
+500,000
+13% +$2.76M
MNPR icon
50
Monopar Therapeutics
MNPR
$674M
$25M 0.51%
270,118
– –
1
2
3 4 5

Similar funds

AAS
Ameritas Advisory Services Lincoln, Nebraska $4.96B AUM 27.52% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
FC
Freemont Capital Singapore $4.9B AUM 11.61% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $4.99B AUM 23.08% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return

Siren LLC's Q2 2026 Portfolio in Review

As of Q2 2026, Siren LLC held 126 positions worth $4.94B, up 37% from $3.61B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Siren LLC deployed $314M of net new capital in Q2 2026, opening 26 new positions and adding to 32 existing holdings. Its largest new stake was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Scholar Rock, an estimated $60.4M trimmed.

  • Siren LLC's largest Q2 2026 buy was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
  • Siren LLC added most to Enliven Therapeutics in Q2 2026, an estimated $43.7M increase.
  • Siren LLC's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $60.4M.
  • Siren LLC fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.8M.
  • Siren LLC's ten largest holdings make up 45% of its $4.94B portfolio in Q2 2026.
  • Siren LLC opened 26 new positions and closed 9 in Q2 2026.
  • Siren LLC's portfolio value rose 37% quarter-over-quarter to $4.94B.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.